Alligator Bioscience announced that a development milestone payment of $6 million has been triggered under their partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech.   The milestone payment is for the agreement to initiate a clinical combination study of ADC-1013 with one of Janssen’s proprietary PD-1 inhibitors. This is the first out of a number of pre-defined milestones, related to the start of combination or phase II studies as part of the ADC-1013 clinical pr...